Senolytics: Clearing Zombie Cells
Senescent cells stop dividing but refuse to die, secreting a toxic cocktail that accelerates aging in surrounding tissue. Can we selectively clear them?
What Are Senescent Cells?
When a cell accumulates enough damage — from telomere shortening, DNA mutations, oxidative stress, or oncogene activation — it faces a choice: repair itself, die (apoptosis), or enter senescence: a state where it permanently stops dividing but remains metabolically active. In youth, this is protective — it prevents damaged cells from becoming cancerous. But with age, senescent cells accumulate because the immune system becomes less efficient at clearing them.
The problem isn't just that they sit there. Senescent cells secrete a toxic mix of inflammatory cytokines, proteases, and growth factors called the SASP (Senescence-Associated Secretory Phenotype). This SASP damages neighboring cells, promotes chronic inflammation, degrades the extracellular matrix, and can even induce senescence in healthy cells — a "bystander effect" that spreads aging through tissue.
The Senolytic Strategy
Senolytics are drugs or compounds that selectively kill senescent cells while sparing healthy ones. The concept was proven in 2015 when James Kirkland's lab at Mayo Clinic showed that clearing senescent cells in mice extended healthspan and improved multiple age-related conditions.
The key insight: senescent cells upregulate anti-apoptotic (pro-survival) pathways to resist death. Senolytics work by inhibiting these survival pathways, tipping senescent cells into apoptosis. Healthy cells don't depend on these same pathways, so they're spared.
The Leading Senolytic Compounds
Dasatinib + Quercetin (D+Q)
Prescription (dasatinib) + OTC supplement
The "gold standard" senolytic combination from Kirkland's lab. Dasatinib is an FDA-approved cancer drug (tyrosine kinase inhibitor); quercetin is a plant flavonoid. Together they clear senescent cells more effectively than either alone. The first human trial (2019) showed D+Q reduced senescent cell markers in patients with diabetic kidney disease.
Catch: Dasatinib is a prescription chemotherapy drug with real side effects (edema, bleeding risk, immune suppression). This is not a casual supplement — it requires medical supervision. We do not list it on our product pages for this reason.
Fisetin
OTC supplement | Emerging evidence
Identified by Mayo Clinic researchers as the most potent naturalsenolytic in a screen of 10 flavonoids. In mice, fisetin reduced senescent cell burden and extended lifespan even when started in old age — a remarkable result. It's found naturally in strawberries (though at ~160x lower concentrations than supplement doses).
The Mayo Clinic is running the AFFIRM-LITE trial testing fisetin in humans. Results are pending. See our full fisetin product page.
Quercetin (alone)
A widely available flavonoid with some senolytic activity. Less potent than D+Q or fisetin in cell culture studies. Has general anti-inflammatory properties. Some people take it as a milder senolytic option, but the evidence for standalone senolytic efficacy in humans is essentially nonexistent.
The Dosing Question: "Hit and Run"
Unlike most supplements that are taken daily, senolytics are theorized to work best in intermittent pulses — what researchers call "hit and run" dosing. The idea: blast senescent cells for 1–3 days, then stop for weeks or months while the body clears the debris and healthy cells remain unaffected.
The mouse studies typically used 2 consecutive days of high-dose treatment per month. Whether this protocol translates to humans is completely unknown. Some people in the biohacker community take high-dose fisetin (~20mg/kg) for 2 days monthly. This is self-experimentation, not evidence-based medicine.
How Would You Know If It's Working?
This is one of the biggest challenges. Currently, there's no convenient consumer test for senescent cell burden. Potential markers include:
- p16INK4a expression: A key senescence marker, but requires tissue biopsy — not practical for consumers.
- SASP factors in blood: IL-6, MCP-1, PAI-1 can be measured via blood tests. A reduction after senolytic treatment would be suggestive but not specific.
- Epigenetic clocks: Theoretically, clearing senescent cells should improve GrimAge score, but this hasn't been demonstrated in published trials.
- Subjective energy and function: Anecdotal, but some self-experimenters report improved energy after senolytic pulses. Take with heavy skepticism.
Our Assessment
Senolytics may be the most promising single strategy in longevity science. The animal data is compelling, the mechanism is logical, and the first human trials are encouraging. But we are still in the early innings. The only natural senolytic that meets our listing criteria is fisetin, and we rate it as Emerging Evidence because the human trial data isn't published yet. If the AFFIRM trial results are positive, this category will move from frontier to mainstream quickly. Until then, treat senolytic self-experimentation as exactly what it is: an educated bet on promising but unproven science.
Key Sources
- Zhu Y, et al. "The Achilles' heel of senescent cells: from transcriptome to senolytic drugs." Aging Cell, 2015. PubMed
- Yousefzadeh MJ, et al. "Fisetin is a senotherapeutic that extends health and lifespan." EBioMedicine, 2018. PubMed
- Hickson LJ, et al. "Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial." EBioMedicine, 2019. PubMed